Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rIL-21 in Metastatic or Recurrent Malignant Melanoma
NCT00514085Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Dec 2007
- Primary completion
- Sep 2010
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human interleukin 21 in Malignant Melanoma (MM), sponsored by Canadian Cancer Trials Group. Started Dec 2007; status: completed.
02
Drugs
recombinant human interleukin 21
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00514085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00514085.